|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
immunosuppressant
|
|
gptkbp:administeredBy
|
subcutaneous injection
intravenous injection
|
|
gptkbp:affiliatedWith
|
immunosuppressants
biologic drugs
disease-modifying antirheumatic drugs
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:FDA
gptkb:EMA
2009
|
|
gptkbp:ATCCode
|
L04AC07
|
|
gptkbp:brand
|
gptkb:RoActemra
gptkb:Actemra
|
|
gptkbp:CASNumber
|
375823-41-9
|
|
gptkbp:contraindication
|
active infection
|
|
gptkbp:developedBy
|
gptkb:Chugai_Pharmaceutical
gptkb:Hoffmann-La_Roche
|
|
gptkbp:eliminatedIn
|
reticuloendothelial system
|
|
gptkbp:halfLife
|
8-14 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tocilizumab
|
|
gptkbp:indication
|
gptkb:juvenile_idiopathic_arthritis
gptkb:giant_cell_arteritis
cytokine release syndrome
moderate to severe rheumatoid arthritis
|
|
gptkbp:isBiosimilarAvailable
|
yes
|
|
gptkbp:KEGGID
|
D08917
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks interleukin-6 receptor
|
|
gptkbp:molecularWeight
|
148000 Da
|
|
gptkbp:monoclonalAntibodyType
|
humanized
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:PubChem_CID
|
DB06273
1201835
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
headache
hypertension
elevated liver enzymes
neutropenia
increased risk of infection
|
|
gptkbp:target
|
gptkb:interleukin-6_receptor
|
|
gptkbp:UNII
|
N7D2JZ6B08
|
|
gptkbp:usedFor
|
gptkb:COVID-19_(severe_cases)
gptkb:giant_cell_arteritis
rheumatoid arthritis
cytokine release syndrome
polyarticular juvenile idiopathic arthritis
systemic juvenile idiopathic arthritis
|
|
gptkbp:bfsParent
|
gptkb:COVID-19_treatments
gptkb:interleukin-6
gptkb:human_interleukin-6
|
|
gptkbp:bfsLayer
|
6
|